<DOC>
	<DOCNO>NCT00329381</DOCNO>
	<brief_summary>In patient least moderate persistent allergic asthma control inhaled steroid , omalizumab ( administer per US product label ) , compare placebo , provide participant significantly improve tolerability specific allergen immunotherapy ( allergy shot ) administer per cluster schedule ( rapid build method ) .</brief_summary>
	<brief_title>Safety Efficacy Study Omalizumab Given Prior Immunotherapy</brief_title>
	<detailed_description>Omalizumab FDA approve anti-IgE drug use treat allergic asthma . This study design give omalizumab 13 week prior administer rapid build specific allergy shot , overlap omalizumab cluster therapy 3 week . The cluster therapy take 4 week complete maintenance dosage last additional 6 week .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>clinical diagnosis history moderate persistent allergic asthma body weight &gt; /= 20kg &lt; /= 150kg Total serum IgE &gt; /= 30 &lt; /= 700IU/mL stable asthma treatment include corticosteroid precede 4 week non smoker least 1 year prior visit 1 patient severe asthma history immunotherapy allergen within past 3 year history anaphylactic allergic reaction upper respiratory tract infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Allergic</keyword>
	<keyword>Asthma</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>